ATE184490T1 - Arzneimittel gegen stress, beeinträchtigung und altwerden und verfahren zu ihrer herstellung - Google Patents

Arzneimittel gegen stress, beeinträchtigung und altwerden und verfahren zu ihrer herstellung

Info

Publication number: ATE184490T1
Authority: AT; Austria
Prior art keywords: stress; drug; impairment; aging; enterosoluble
Prior art date: 1994-06-02

Application number

AT94919023T

Other languages

English (en)

Inventor

Dan Riga

Sorin Riga

Original Assignee

Dan Riga

Sorin Riga

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-06-02

Filing date

1994-06-02

Publication date

1999-10-15

1994-06-02 Application filed by Dan Riga, Sorin Riga filed Critical Dan Riga

1999-10-15 Application granted granted Critical

1999-10-15 Publication of ATE184490T1 publication Critical patent/ATE184490T1/de

Links

238000004519 manufacturing process Methods 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
230000032683 aging Effects 0.000 title 1
230000006735 deficit Effects 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
230000035882 stress Effects 0.000 title 1
229940079593 drug Drugs 0.000 abstract 4
239000003814 drug Substances 0.000 abstract 4
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
229930091371 Fructose Natural products 0.000 abstract 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 1
239000005715 Fructose Substances 0.000 abstract 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
QKHNQACCGKTTKA-UHFFFAOYSA-N O(C1=CC=CC=C1)CC(=O)OC(C)N Chemical class O(C1=CC=CC=C1)CC(=O)OC(C)N QKHNQACCGKTTKA-UHFFFAOYSA-N 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
229930003451 Vitamin B1 Natural products 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
150000003869 acetamides Chemical class 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
230000001195 anabolic effect Effects 0.000 abstract 1
230000003712 anti-aging effect Effects 0.000 abstract 1
230000002180 anti-stress Effects 0.000 abstract 1
230000001147 anti-toxic effect Effects 0.000 abstract 1
229940009098 aspartate Drugs 0.000 abstract 1
239000002775 capsule Substances 0.000 abstract 1
150000007942 carboxylates Chemical class 0.000 abstract 1
230000001925 catabolic effect Effects 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
230000003284 homeostatic effect Effects 0.000 abstract 1
239000011630 iodine Substances 0.000 abstract 1
229910052740 iodine Inorganic materials 0.000 abstract 1
229910052744 lithium Inorganic materials 0.000 abstract 1
239000011777 magnesium Substances 0.000 abstract 1
229910052749 magnesium Inorganic materials 0.000 abstract 1
229930182817 methionine Natural products 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
QMEYHMGPFYXWNU-UHFFFAOYSA-N n-(2-aminoethyl)-2-phenoxyacetamide Chemical class NCCNC(=O)COC1=CC=CC=C1 QMEYHMGPFYXWNU-UHFFFAOYSA-N 0.000 abstract 1
230000000444 normolipidemic effect Effects 0.000 abstract 1
230000001590 oxidative effect Effects 0.000 abstract 1
230000001717 pathogenic effect Effects 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
229910052700 potassium Inorganic materials 0.000 abstract 1
239000011591 potassium Substances 0.000 abstract 1
230000002035 prolonged effect Effects 0.000 abstract 1
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
230000002195 synergetic effect Effects 0.000 abstract 1
229960003495 thiamine Drugs 0.000 abstract 1
DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
230000000304 vasodilatating effect Effects 0.000 abstract 1
229940124549 vasodilator Drugs 0.000 abstract 1
239000003071 vasodilator agent Substances 0.000 abstract 1
235000010374 vitamin B1 Nutrition 0.000 abstract 1
239000011691 vitamin B1 Substances 0.000 abstract 1
235000019158 vitamin B6 Nutrition 0.000 abstract 1
239000011726 vitamin B6 Substances 0.000 abstract 1
229940011671 vitamin b6 Drugs 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Materials For Medical Uses (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT94919023T 1994-06-02 1994-06-02 Arzneimittel gegen stress, beeinträchtigung und altwerden und verfahren zu ihrer herstellung ATE184490T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/RO1994/000003 WO1995033486A1 (en)	1994-06-02	1994-06-02	Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof
BR9408581A BR9408581A (pt)	1994-06-02	1994-06-02	Medicamento anti-tens o anti-incapacitação e anti-envelhecimento e processo para a sua produção

Publications (1)

Publication Number	Publication Date
ATE184490T1 true ATE184490T1 (de)	1999-10-15

Family

ID=25664670

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94919023T ATE184490T1 (de)	1994-06-02	1994-06-02	Arzneimittel gegen stress, beeinträchtigung und altwerden und verfahren zu ihrer herstellung

Country Status (11)

Country	Link
US (1)	US6174890B1 (de)
EP (1)	EP0804239B1 (de)
JP (1)	JP3455544B2 (de)
AT (1)	ATE184490T1 (de)
AU (1)	AU694125B2 (de)
BR (1)	BR9408581A (de)
CA (1)	CA2191837C (de)
DE (1)	DE69420746T2 (de)
DK (1)	DK0804239T3 (de)
ES (1)	ES2139077T3 (de)
WO (1)	WO1995033486A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5703127A (en) *	1996-01-25	1997-12-30	Pak; Kyoungsik	Composition, dosage unit, and method for treating stomach disorders
GB2312621B (en) *	1996-05-02	1998-03-11	Pharma Nord Uk Limited	Anti-oxidant medicament
PT1143954E (pt) *	1998-12-01	2004-12-31	Univ Kentucky Res Found	Utilizacao de derivados de acido nocotinico para o tratamento de danos no adn em celulas da pele
US6726939B1 (en)	2000-03-22	2004-04-27	Kyoungsik Pak	Composition and method for reducing blood pressure, alleviating or eliminating angina pectoris and headaches, and enhancing skin and hair
DE10018834A1 (de) *	2000-04-15	2001-10-25	Lohmann Therapie Syst Lts	Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
EA005383B1 (ru) *	2001-12-28	2005-02-24	Федеральное Государственное Унитарное Предприятие "Центр Экстремальной Медицины"	Способ фармакологической коррекции работоспособности человека в экстремальных ситуациях
US20040001817A1 (en) *	2002-05-14	2004-01-01	Giampapa Vincent C.	Anti-aging nutritional supplement
WO2004026296A1 (ja) *	2002-09-18	2004-04-01	Ajinomoto Co., Inc.	抗ストレス性疾患組成物
ITRN20030021A1 (it) *	2003-07-21	2005-01-22	Ascor Chimici Srl	Composizione di materia comprendente particelle contenenti cloruro di colina da somministrare in forma ruminalmente protetta e post-ruminalmente efficace.
US20050214388A1 (en) *	2004-02-18	2005-09-29	Gorham Thomas R	Multivitamin formulations containing controlled-release magnesium
EP1750766B1 (de)	2004-05-11	2013-07-03	Emotional Brain B.V.	Pharmazeutische Formulierungen und ihre Verwendungen bei der Behandlung von weiblicher sexueller Dysfunktion
ITMI20041820A1 (it) *	2004-09-24	2004-12-24	Ascor Chimici Srl	Composizione in micro-pellets a rilascio controllato di sostanze fisiologicamente attive, procedimento di preparazione e relativo impiego nel settore zootecnico.
US20060153900A1 (en) *	2005-01-13	2006-07-13	Pins Joel J	Dietary supplement for treatment of lipid risk factors
US20060252830A1 (en) *	2005-05-06	2006-11-09	Brandon Stephen F	Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) *	2005-05-06	2006-11-09	Christopher Offen	Method for the treatment of magnesium and potassium deficiencies
US8263137B2 (en) *	2005-08-04	2012-09-11	Vertical Pharmaceuticals, Inc.	Nutritional supplement for women
US8202546B2 (en) *	2005-08-04	2012-06-19	Vertical Pharmaceuticals, Inc.	Nutritional supplement for use under physiologically stressful conditions
US7901710B2 (en) *	2005-08-04	2011-03-08	Vertical Pharmaceuticals, Inc.	Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) *	2005-08-04	2011-08-16	Vertical Pharmaceuticals, Inc.	Nutritional supplement for women
EP1790343A1 (de)	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
WO2007073006A1 (ja) *	2005-12-22	2007-06-28	Keio University	細胞保護性を有するアミノ酸の増加誘導剤及び増加方法
RU2330659C1 (ru) *	2006-10-23	2008-08-10	ФГУ Российский научно-исследовательский нейрохирургический институт им. проф. А.Л. Поленова	Способ лечения диэнцефально-катаболического синдрома
EP1925307A1 (de)	2006-11-03	2008-05-28	Emotional Brain B.V.	Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
JP2008174512A (ja) *	2007-01-22	2008-07-31	Kracie Seiyaku Kk	起床時疲労感改善用組成物
JP5788715B2 (ja) *	2011-05-31	2015-10-07	キリンホールディングス株式会社	酸素消費量及びエネルギー消費量の低減剤
TW201739455A (zh)	2016-04-19	2017-11-16	菲林公司	菸鹼醯胺的口服醫藥組成物
WO2019161331A1 (en) *	2018-02-19	2019-08-22	Marshall Timothy M	Magnesium/lithium preparations for neuroprotection and neurotrophic benefits
JP2021161045A (ja) *	2020-03-31	2021-10-11	株式会社古川リサーチオフィス	亜鉛化合物配合組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3493659A (en)	1967-10-23	1970-02-03	Hoffmann La Roche	Compositions and process for the production thereof

1994
- 1994-06-02 JP JP50071396A patent/JP3455544B2/ja not_active Expired - Fee Related
- 1994-06-02 US US08/750,159 patent/US6174890B1/en not_active Expired - Lifetime
- 1994-06-02 AT AT94919023T patent/ATE184490T1/de active
- 1994-06-02 BR BR9408581A patent/BR9408581A/pt not_active Application Discontinuation
- 1994-06-02 CA CA002191837A patent/CA2191837C/en not_active Expired - Lifetime
- 1994-06-02 DE DE69420746T patent/DE69420746T2/de not_active Expired - Lifetime
- 1994-06-02 DK DK94919023T patent/DK0804239T3/da active
- 1994-06-02 EP EP94919023A patent/EP0804239B1/de not_active Expired - Lifetime
- 1994-06-02 ES ES94919023T patent/ES2139077T3/es not_active Expired - Lifetime
- 1994-06-02 WO PCT/RO1994/000003 patent/WO1995033486A1/en not_active Ceased
- 1994-06-02 AU AU70104/94A patent/AU694125B2/en not_active Ceased

Also Published As

Publication number	Publication date
ES2139077T3 (es)	2000-02-01
EP0804239A1 (de)	1997-11-05
WO1995033486A1 (en)	1995-12-14
AU694125B2 (en)	1998-07-16
BR9408581A (pt)	1997-08-26
CA2191837A1 (en)	1995-12-14
DE69420746T2 (de)	2000-06-29
DK0804239T3 (da)	2000-04-03
DE69420746D1 (de)	1999-10-21
JP3455544B2 (ja)	2003-10-14
CA2191837C (en)	2002-10-15
EP0804239B1 (de)	1999-09-15
US6174890B1 (en)	2001-01-16
JPH10500137A (ja)	1998-01-06
AU7010494A (en)	1996-01-04

Publication	Publication Date	Title
ATE184490T1 (de)	1999-10-15	Arzneimittel gegen stress, beeinträchtigung und altwerden und verfahren zu ihrer herstellung
PT100234A (pt)	1993-07-30	Novos esteres de alcoois aminados biciclicos e triciclicos, processo para a sua preparacao
EP0654484B1 (de)	2003-04-23	Arzneimittelzubereitungen enthaltend Thioctsäure oder Dihydroliponsäure in Form von Einschlussverbindungen mit Cyclodextrinen und in Form von Granulaten, Kau- oder Brausetabletten
DE247983T1 (de)	1990-09-27	Arzneizubereitung zur oralen anwendung.
EP2358360B1 (de)	2016-09-14	Formulierungen enthaltend ein 2-oxo-1-pyrrolidin-derivat mit verlängerter freisetzung
CA2407072A1 (en)	2001-11-01	Taste masking coating composition
NZ229310A (en)	1991-10-25	4-(quinolin-2-ylmethoxy) phenylacetic acid derivatives and pharmaceutical compositions
ATE101340T1 (de)	1994-02-15	Neue arzneimittelformulierung sowie verfahren zu deren herstellung.
HUP0301887A2 (hu)	2003-09-29	Több részecskébżl álló gyógyszerforma, amely legalább két különbözżen bevont pelletformát tartalmaz
AU9072282A (en)	1983-05-26	Oral controlled release multiple unit formulation
CA2330480A1 (en)	2000-06-29	Controlled release formulation of divalproex sodium
AU4846690A (en)	1990-08-13	Polyunsaturated fatty acid derivatives, pharmaceutical compositions containing the same, method for the preparation thereof, and their use as medicament
EE03089B1 (et)	1998-06-15	Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod
CA2625554C (en)	2011-08-09	Enteric soft capsule comprising valproic acid
IT1270239B (it)	1997-04-29	Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
ATE259369T1 (de)	2004-02-15	Neue geranylgeranylderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen
AU3071300A (en)	2000-08-07	Multiparticulate bisoprolol formulation
CN115590801A (zh)	2023-01-13	一种紧致、抗衰、修复型护肤组合物及其应用
EP0250578B1 (de)	1991-04-10	Verfahren zur herstellung von einzeln dosierten darreichungsformen sowie die danach erhältlichen darreichungsformen
FR2740135B1 (fr)	1997-12-19	Nouveaux derives de pyrazoles acides, leur procede de preparation, leur application a titre de medicaments, leur nouvelle utilisation et les compositions pharmaceutiques les renfermant
ATE136783T1 (de)	1996-05-15	Arzneimittel mit antineoplastischer wirkung enthaltend als wirkstoff octadecyl-(2-(n- methylpiperidino)-ethyl>-phosphat und verfahren zu dessen herstellung
WO2004089333A3 (en)	2005-02-03	A stable benzimidazole formulation
US11690829B2 (en)	2023-07-04	Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
WO2002074922A3 (en)	2003-02-20	Compositions and methods for modulating an immune response
WO2000025765A3 (de)	2000-08-03	Wässrige arzneimittelformulierung zur oralen applikation